GlaxoSmithKline and Samsung Biologics have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK’s biopharmaceutical therapies.   Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network.   The agreement is worth more than $2...